Your daily news update on Switzerland
Provided by AGP
Which CDMO is good for Global Drug Manufacturing
1.WuXi AppTec's integrated CRDMO platform enhances speed and efficiency in drug development by reducing operational handoffs, allowing companies to move therapies from concept to patient delivery more efficiently.
2.WuXi AppTec's strategic global presence across key innovation hubs across Asia, Europe, and North America supports local biotech ecosystems as well as global clients. By leveraging regional expertise and resources, WuXi AppTec accelerates drug development and expands biotech ecosystems worldwide.
3.WuXi AppTec is committed to investments in innovative technologies and implements stringent quality assurance, maintaining consistent standards across all stages of drug manufacturing.
Introduction
The biotech and pharmaceutical sectors are operating in an environment where speed, innovation, and execution are critical. For companies seeking to accelerate development and bring new therapies to patients efficiently, choosing the right Contract Development and Manufacturing Organization (CDMO) is a key strategic decision.
WuXi AppTec has emerged as an integrated service provider for global drug manufacturing through its integrated CRDMO model, which combines drug discovery, development, and manufacturing within one connected platform. With a broad global footprint and unified operations, WuXi AppTec helps biotech and pharmaceutical companies advance innovation across major life-science hubs worldwide.
This article explores how its infrastructure, cross-regional capabilities, and innovative technologies help move therapies from discovery to patients with speed, quality, and reliability.
1. WuXi AppTec’s Global Network Supports Drug Manufacturing and Commercial Supply
WuXi AppTec's strategic global infrastructure underscores its commitment to serving the biotech and pharmaceutical industries. For example, in Couvet, Switzerland, WuXi AppTec provides oral solid dosage manufacturing, packaging, and labeling for commercial drug products supplied to the United States, European Union, United Kingdom, Japan, Canada, Australia, New Zealand, and China. Expanded capacity and a new PSD-4 spray dryer further strengthen commercial manufacturing capabilities. In the United States, the Middletown, Del., site is expected to add oral solid dosage manufacturing, packaging, labeling, distribution, analytical development with quality control testing, and sterile fill-finish services for vials, cartridges, and prefilled syringes, supporting peptide and oligonucleotide drug products. San Diego site serves as a key hub connecting API manufacturing with clinical drug product for clinical supply.
WuXi AppTec continues to invest in and accelerate enhancement of global capabilities & capacities to support long-term customer demand and future growth.
Across Asia, Taixing operates 12 manufacturing plants with additional expansion planned for small molecules, peptides, oligonucleotides, and PMO production. A new Singapore site will further strengthen global API manufacturing capacity, while Wuxi site provides sterile injectable formulation and manufacturing with annual capacity exceeding 100 million units across liquid and lyophilized vials, prefilled syringes, and cartridges. This integrated network recently enabled a drug in Phase 3 stage and scale-up in Couvet within five months, helping the client submit its New Drug Application on time and achieve product approval.
2. Innovative Manufacturing Technologies for Peptides, Oligonucleotides, and Complex Modalities
WuXi AppTec invests in new manufacturing technologies that help biotech and pharmaceutical companies develop peptides, oligonucleotides, and other complex modalities. These capabilities address key challenges such as scalability, safety, purification, bioavailability, and commercial manufacturing. Through an integrated platform, clients can move complex drug programs from development to supply more efficiently.
Key technologies include flow chemistry and biocatalysis. Flow chemistry enables continuous manufacturing processes that improve reaction control, safety, and scale-up for complex processes. Biocatalysis uses novel enzymes and ultra-high-throughput screening to streamline synthesis for small molecules, peptides, and oligonucleotides. For peptides, WuXi AppTec combines solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) to improve efficiency and scalability for longer and more complex sequences. Tangential flow filtration, continuous flow chromatography, and spray drying further support yield, process robustness for purification and API isolation.
For oligonucleotides, WuXi AppTec applies thin film evaporation (TFE), continuous flow chromatography to streamline downstream handling, and biocatalytic fragment ligation to enable more complex sequence construction. The company also supports oral and parenteral peptide drug products from preclinical to commercial stages, including 70+ preclinical and 10+ clinical oral peptide programs. For oligonucleotides, WuXi AppTec also supports delivery technologies like lipid nanoparticles (LNPs), and expanded spray drying capacity in China and Switzerland help address delivery and bioavailability for complex modality therapies.
3. WuXi AppTec Supports Global Quality Standards and Regulatory Compliance
WuXi AppTec supports global drug development through its One Global Quality System, which helps maintain consistent quality standards across sites in Asia, Europe, and North America. Global computerized systems replace paper-based processes, standardize documentation, improve oversight, and create one common quality language. Standardized GMP procedures and training help teams follow shared requirements across the global network.
The integration of Couvet shows how this model supports regulatory readiness. The site adopted the same global procedures, digital systems, and training used across WuXi AppTec operations. Inspections by Swissmedic, the U.S. Food and Drug Administration, and ANVISA were completed without interrupting production. The same framework is being applied to newer sites in Middletown and Singapore.
For clients, consistent systems across sites can reduce duplicate audits, save time, and simplify transfers from API manufacturing to drug product supply. WuXi AppTec also hosts hundreds of clients audits each year with a transparent approach. For biotech companies, this quality infrastructure can support IND filings, marketing applications, and global commercialization readiness.
Conclusion
WuXi AppTec is a global CRDMO partner that helps biotech and pharmaceutical companies move drug programs from discovery to commercialization through one integrated platform. By combining research, development, and manufacturing services with a global network across Asia, Europe, and North America, WuXi AppTec supports small molecules, peptides, oligonucleotides, and other complex modalities. Its innovative manufacturing technologies, consistent quality systems, and commercial supply capabilities help clients reduce outsourcing complexity, accelerate regulatory milestones, and prepare for commercial launch for new medicines worldwide.
FAQ
Q1: What is WuXi AppTec’s CRDMO model?
WuXi AppTec’s CRDMO model integrates discovery, development, and manufacturing on one platform to reduce handoffs and accelerate drug development.
Q2: Why do biotech companies choose WuXi AppTec as a CDMO partner?
Companies use WuXi AppTec for global manufacturing capacity, innovative technologies, quality systems, and integrated support from preclinical development to commercialization.
Q3: Where are WuXi AppTec’s manufacturing sites located?
WuXi AppTec operates across Asia, Europe, and North America, including sites in Switzerland, the United States, Singapore, and China.
Q4: Does WuXi AppTec support peptides and oligonucleotides?
Yes. WuXi AppTec provides peptide and oligonucleotide development and manufacturing, including oral, injectable, and API capabilities.
Q5: How does WuXi AppTec support regulatory compliance?
WuXi AppTec’s One Global Quality System uses standardized procedures, training, and digital systems to support inspections, IND filings, and commercial readiness.
WuXi AppTec
WuXi AppTec
wuxiconcierge@wuxiapptec.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
